tert-butyl (S)-4-(4-(5-(cyclopropanecarboxamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazine-1-carboxylate | 1140171-56-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl (S)-4-(4-(5-(cyclopropanecarboxamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazine-1-carboxylate
• CAS: 1140171-56-7
• 化学式: C₂₃H₃₁FN₄O₅
• 分子量: 462.521
• InChiKey: CVKXCLPWHFANOB-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.73
• 重原子数：
  33.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  91.42
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-4-(4-(5-(cyclopropanecarboxamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents

  摘要：

  Novel oxazolidinone antibacterials bearing a variety of 3-indolylglyoxamide substituents have been explored in an effort to improve the spectrum and potency of this class of agents. A subclass of this series was also made with the diversity at C-5 terminus. These derivatives have been screened against a panel of clinically relevant Gram-positive pathogens and fastidious Gram-negative organisms. Several analogs in this series were identified with in vitro activity superior to linezolid ( MIC = 0.25-2 mu g/ mL). Compounds 10a, 10c, 10e and 10f displayed activity against linezolid resistant Gram-positive organisms (MIC = 2-4 mu g/ mL). Selected oxazolidinones were evaluated for in vivo efficacy against a mouse systemic infection model. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.043
• 作为产物：
  描述：

  (S)-叔丁基-4-(4-(5-(氨甲基)-2-羰基恶唑烷酮-3-基)-2-氟苯基)哌嗪-1-羧酸 、 环丙甲酸 在 N-甲基吗啉 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以65%的产率得到tert-butyl (S)-4-(4-(5-(cyclopropanecarboxamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents

  摘要：

  Novel oxazolidinone antibacterials bearing a variety of 3-indolylglyoxamide substituents have been explored in an effort to improve the spectrum and potency of this class of agents. A subclass of this series was also made with the diversity at C-5 terminus. These derivatives have been screened against a panel of clinically relevant Gram-positive pathogens and fastidious Gram-negative organisms. Several analogs in this series were identified with in vitro activity superior to linezolid ( MIC = 0.25-2 mu g/ mL). Compounds 10a, 10c, 10e and 10f displayed activity against linezolid resistant Gram-positive organisms (MIC = 2-4 mu g/ mL). Selected oxazolidinones were evaluated for in vivo efficacy against a mouse systemic infection model. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.043